Opko Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average cost of $5.96 per share, for a total transaction of $298,000.00. Following the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $18,290,947.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, August 16th, Phillip Md Et Al Frost purchased 40,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.04 per share, for a total transaction of $241,600.00.
  • On Tuesday, August 15th, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.08 per share, for a total transaction of $152,000.00.
  • On Monday, August 14th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.15 per share, for a total transaction of $61,500.00.
  • On Friday, August 11th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.19 per share, for a total transaction of $61,900.00.
  • On Thursday, August 10th, Phillip Md Et Al Frost purchased 39,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.23 per share, for a total transaction of $242,970.00.
  • On Wednesday, August 9th, Phillip Md Et Al Frost purchased 18,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.35 per share, for a total transaction of $114,300.00.
  • On Tuesday, August 8th, Phillip Md Et Al Frost purchased 5,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.05 per share, for a total transaction of $30,250.00.
  • On Wednesday, August 2nd, Phillip Md Et Al Frost purchased 25,000 shares of Opko Health stock. The shares were acquired at an average cost of $6.15 per share, for a total transaction of $153,750.00.
  • On Tuesday, August 1st, Phillip Md Et Al Frost purchased 46,600 shares of Opko Health stock. The shares were acquired at an average cost of $6.25 per share, for a total transaction of $291,250.00.
  • On Friday, July 28th, Phillip Md Et Al Frost purchased 35,100 shares of Opko Health stock. The shares were acquired at an average cost of $6.30 per share, for a total transaction of $221,130.00.

Opko Health, Inc. (NASDAQ:OPK) traded up 1.19% on Friday, reaching $5.95. 1,430,918 shares of the company’s stock were exchanged. Opko Health, Inc. has a one year low of $5.85 and a one year high of $12.15. The firm’s market cap is $3.33 billion. The firm has a 50 day moving average price of $6.28 and a 200 day moving average price of $7.21.

Opko Health (NASDAQ:OPK) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01. Opko Health had a negative return on equity of 3.67% and a negative net margin of 6.52%. The business had revenue of $314.20 million for the quarter, compared to analyst estimates of $322.64 million. During the same quarter in the previous year, the firm earned $0.02 EPS. The company’s quarterly revenue was down 12.0% compared to the same quarter last year. On average, equities analysts anticipate that Opko Health, Inc. will post ($0.21) earnings per share for the current year.

WARNING: “Phillip Md Et Al Frost Buys 50,000 Shares of Opko Health, Inc. (OPK) Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/18/phillip-md-et-al-frost-buys-50000-shares-of-opko-health-inc-opk-stock.html.

OPK has been the topic of a number of recent research reports. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and set a $19.50 price target on shares of Opko Health in a research note on Friday, June 16th. Zacks Investment Research downgraded shares of Opko Health from a “buy” rating to a “hold” rating in a research note on Saturday, August 12th. Jefferies Group LLC reaffirmed a “hold” rating and set a $6.50 price target (down previously from $6.80) on shares of Opko Health in a research note on Thursday, August 10th. Finally, Barrington Research boosted their price objective on shares of Opko Health to $11.00 and gave the company an “outperform” rating in a research report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Opko Health has a consensus rating of “Buy” and an average target price of $15.28.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Financial Architects Inc increased its stake in shares of Opko Health by 45.0% in the second quarter. Financial Architects Inc now owns 15,460 shares of the biotechnology company’s stock worth $102,000 after buying an additional 4,800 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Opko Health during the fourth quarter worth about $105,000. Blair William & Co. IL acquired a new stake in shares of Opko Health during the second quarter worth about $112,000. Timber Hill LLC acquired a new stake in shares of Opko Health during the first quarter worth about $114,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Opko Health during the second quarter worth about $117,000. Institutional investors and hedge funds own 22.94% of the company’s stock.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.